Hovedbudskap
Ved akutt anfall av urinsyregikt er ikke-steroidale antiiflammatotiske legemidler førstevalg, med intraartikulære kortisoninjeksjoner eller peroral kolkisin som alternativer
Ved flere anfall med urinsyregikt i året er langtidsbehandling med allopurinol, probenecid eller kolkisin aktuelt
Nyere dyreeksperimentell forskning har utfordret dagens avventende terapeutiske holdning ved asymptomatisk hyperurikemi
- 1.
Høieggen A. Behandling av arthritis urica og hyperurikemi. Tidsskr Nor Lægeforen 1992; 112: 1038 – 40.
- 2.
Becker MA. Clinical aspects of monosodium urate monohydrate crystal deposition disease (gout). Rheum Dis Clin North Am 1988; 14: 377 – 94.
- 3.
McGill NW. Gout and other crystal-associated arthropathies. Baillieres Best Pract Res Clin Rheumatol 2000; 14: 445 – 60.
- 4.
Selby JV, Friedman GD, Quesenberry CP jr. Precursors of essential hypertension: pulmonary function, heart rate, uric acid, serum cholesterol, and other serum chemistries. Am J Epidemiol 1990; 131: 1017 – 27.
- 5.
Jossa F, Farinaro E, Panico S, Krogh V, Celentano E, Galosso R et al. Serum uric acid and hypertension: the Olivetti heart study. J Hum Hypertens 1994; 8: 677 – 81.
- 6.
Talbott JH, Terplan KL. The kidney in gout. Medicine 1960; 39: 405 – 67.
- 7.
Cannon PJ, Stason WB, Demartini FE, Sommers SC, Laragh JH. Hyperuricemia in primary and renal hypertension. N Engl J Med 1966; 275: 457 – 64.
- 8.
Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971 – 1992. National Health and Nutrition Examination Survey. JAMA 2000; 283: 2404 – 10.
- 9.
Verdecchia P, Schillaci G, Reboldi G, Santeusanio F, Porcellati C, Brunetti P. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. Hypertension 2000; 36: 1072 – 8.
- 10.
Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 1999; 131: 7 – 13.
- 11.
Johnson RJ, Kivlighn SD, Kim YG, Suga S, Fogo AB. Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease. Am J Kidney Dis 1999; 33: 225 – 34.
- 12.
The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997; 157: 2413 – 46.
- 13.
Grundy SM, Balady GJ, Criqui MH, Fletcher H, Greenland G, Hiratzka LF et al. Primary prevention of coronary heart disease: guidance from Framingham: a statement for healthcare professionals from the AHA Task Force on Risk Reduction. American Heart Association. Circulation 1998; 97: 1876 – 87.
- 14.
Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001; 38: 1101 – 6.
- 15.
Nakagawa T, Mazzali M, Kang DH, Kanellis J, Watanabe S, Sanchez-Lozada LF et al. Hyperuricemia causes glomerular hypertrophy in the rat. Am J Nephrol 2003; 23: 2 – 7.
- 16.
Kang DH, Nakagawa T, Feng L, Watanabe S, Han L, Mazzali M et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol 2002; 13: 2888 – 97.
- 17.
Schumacher HR jr., Boice JA, Daikh DI, Mukhopadhyay S, Malmstrom K, Ng J et al. Randomised double blind trial of etoricoxib and indomethacin in treatment of acute gouty arthritis. BMJ 2002; 324: 1488 – 92.
- 18.
Ahern MJ, Reid C, Gordon TP, McCredie M, Brooks PM, Jones M. Does colchicine work? The results of the first controlled study in acute gout. Aust N Z J Med 1987; 17: 301 – 4.
- 19.
Midler ved krystallartritter. I: Norsk legemiddelhåndbok for helsepersonell. Oslo: Foreningen for utgivelse av Norsk legemiddelhåndbok, Den norske lægeforening, 2002: 1050.
- 20.
Ellis S, Isenberg D. Controlling hyperuricaemia in general practice. Practitioner 1999; 243: 886 – 91.
- 21.
Lange U, Schumann C, Schmidt KL. Current aspects of colchicine therapy -- classical indications and new therapeutic uses. Eur J Med Res 2001; 6: 150 – 60.
- 22.
Wortmann RL. Effective management of gout: an analogy. Am J Med 1998; 105: 513 – 4.
- 23.
Alloway JA, Moriarty MJ, Hoogland YT, Nashel DJ. Comparison of triamcinolone acetonide with indomethacin in the treatment of acute gouty arthritis. J Rheumatol 1993; 20: 111 – 3.
- 24.
Pouliot M, James MJ, McColl SR, Naccache PH, Cleland LG. Monosodium urate microcrystals induce cyclooxygenase-2 in human monocytes. Blood 1998; 91: 1769 – 76.
- 25.
Gran JT, Gundersen T. Allopurinol – hypersensitivitetssyndromet. Tidsskr Nor Lægeforen 1989; 109: 3102 – 4.
- 26.
Simkin PA. When, why, and how should we quantify the excretion rate of urinary uric acid? J Rheumatol 2001; 28: 1207 – 10.
- 27.
Caspi D, Lubart E, Graff E, Habot B, Yaron M, Segal R. The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients. Arthritis Rheum 2000; 43: 103 – 8.
- 28.
Harris M, Bryant LR, Danaher P, Alloway J. Effect of low dose daily aspirin on serum urate levels and urinary excretion in patients receiving probenecid for gouty arthritis. J Rheumatol 2000; 27: 2873 – 6.
- 29.
Wurzner G, Gerster JC, Chiolero A, Maillard M, Fallab-Stubi CL, Brunner HR et al. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. J Hypertens 2001; 19: 1855 – 60.
- 30.
Kamper AL, Nielsen AH. Uricosuric effect of losartan in patients with renal transplants. Transplantation 2001; 72: 671 – 4.
- 31.
Schmidt A, Gruber U, Bohmig G, Koller E, Mayer G. The effect of ACE inhibitor and angiotensin II receptor antagonist therapy on serum uric acid levels and potassium homeostasis in hypertensive renal transplant recipients treated with CsA. Nephrol Dial Transplant 2001; 16: 1034 – 7.
- 32.
Feher MD, Hepburn AL, Hogarth MB, Ball SG, Kaye SA. Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout. Rheumatology 2003; 42: 321 – 5.
- 33.
Perkins P, Jones AC. Gout. Ann Rheum Dis 1999; 58: 611 – 7.
- 34.
Ferraz MB. An evidence based appraisal of the management of nontophaceous interval gout. J Rheumatol 1995; 22: 1618 – 9.
- 35.
Fam AG. Should patients with interval gout be treated with urate lowering drugs? J Rheumatol 1995; 22: 1621 – 3.
- 36.
Ferraz MB, O’Brien B. A cost effectiveness analysis of urate lowering drugs in nontophaceous recurrent gouty arthritis. J Rheumatol 1995; 22: 908 – 14.
- 37.
Schlesinger N, Baker DG, Schumacher HR jr. How well have diagnostic tests and therapies for gout been evaluated? Curr Opin Rheumatol 1999; 11: 441 – 5.
- 38.
Dessein PH, Shipton EA, Stanwix AE, Joffe BI, Ramokgadi J. Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study. Ann Rheum Dis 2000; 59: 539 – 43.
- 39.
Liang MH, Fries JF. Asymptomatic hyperuricemia: the case for conservative management. Ann Intern Med 1978; 88: 666 – 70.